Dauntless Investment Group LLC Purchases Shares of 91,540 Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Key Points

• Dauntless Investment Group LLC acquired 91,540 shares of Aquestive Therapeutics, Inc. in the first quarter, valued at approximately $265,000, representing about 0.09% of the company's stock.
• Aquestive Therapeutics recently reported earnings of ($0.24) EPS, missing analysts' expectations, with quarterly revenue of $8.72 million compared to expected $12.23 million.
• Research analysts maintain a positive outlook on AQST shares, with an average rating of "Buy" and a target price of $10.14.

Dauntless Investment Group LLC acquired a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 91,540 shares of the company's stock, valued at approximately $265,000. Dauntless Investment Group LLC owned about 0.09% of Aquestive Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of AQST. Summit Wealth & Retirement Planning Inc. purchased a new position in shares of Aquestive Therapeutics in the first quarter worth about $29,000. Victory Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics in the first quarter worth about $31,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Aquestive Therapeutics in the first quarter worth about $33,000. Dynamic Technology Lab Private Ltd purchased a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $44,000. Finally, Two Sigma Advisers LP purchased a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $57,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Trading Down 3.6%

Shares of AQST opened at $4.00 on Tuesday. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $5.80. The stock's 50 day moving average is $3.44 and its two-hundred day moving average is $3.07. The firm has a market cap of $397.32 million, a P/E ratio of -6.78 and a beta of 1.97.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analysts' expectations of $12.23 million. Equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AQST shares. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer started coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.